Novo Nordisk Lowers Cash-Pay Prices for Wegovy and Ozempic
Novo Nordisk announced on Monday that it is reducing the direct-to-consumer monthly price of Wegovy and Ozempic to $349 for existing cash-paying patients, down from $499. The company said the highest dose of Ozempic will remain priced at $499 per month.
Alongside the permanent price cut, Novo Nordisk launched a temporary introductory program:
- New cash-paying patients can access the two lowest doses of Wegovy or Ozempic for $199/month for their first two months of treatment.
- After that period, patients move to the new $349 monthly rate.
- The introductory offer runs through March 31.
The adjustments arrive as drugmakers and federal officials attempt to make high-demand GLP-1 medications easier for Americans to access. These drugs — now central to both weight-loss and diabetes treatment — have seen surging demand and varying insurance coverage, prompting companies to expand direct-to-consumer options.
Broader Push to Expand Affordability
The updated pricing strategy reflects a larger shift in how GLP-1 medications are being distributed and financed. Recent agreements between policymakers and drugmakers target:
- Lower prices paid through government channels
- Expanded Medicare coverage for certain obesity treatments
- Broader availability on a new federal direct-to-consumer platform launching in January
- Lower cash-pay costs through direct manufacturer programs
Eli Lilly responded to the same policy efforts by reducing prices on its LillyDirect platform. Its weight-loss injection Zepbound now starts at $299/month, with higher doses ranging up to $449.
Novo Nordisk is coordinating with major retailers and telehealth partners to broaden distribution of the new pricing, including Costco, GoodRx, WeightWatchers, Ro, LifeMD, eMed, and its own NovoCare pharmacy.
What Access Looks Like Going Forward
GLP-1 treatments remain among the fastest-growing drug categories in the U.S., but coverage gaps continue to push patients toward self-pay programs. Novo Nordisk’s updated model is designed to:
- Reduce initial barriers for new patients
- Lower long-term out-of-pocket spending
- Create alignment with upcoming public-sector pricing frameworks
- Strengthen distribution through retail and telehealth ecosystems
As competition intensifies between Wegovy, Ozempic, Zepbound, and Mounjaro, direct-to-consumer pricing is becoming a key battleground.
WSA Take
The GLP-1 price cuts mark a meaningful shift in the economics of weight-loss and diabetes care. As drugmakers adjust pricing ahead of broader policy changes, the market is signaling a push toward mass-market adoption rather than premium-tier accessibility.
For investors, expanded affordability could solidify long-term demand — but it also accelerates competition and margin pressure across the sector.
Read our recent coverage on Berkshire’s New $4.3B Position.
Explore more insights on the Wall Street Access homepage.
Disclaimer:
Wall Street Access does not work with or receive compensation from any public companies mentioned. Content is for informational and educational purposes only.
